KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $270.8 million.

  • Biomarin Pharmaceutical's Other Non-Current Assets rose 3585.65% to $270.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $270.8 million, marking a year-over-year increase of 3585.65%. This contributed to the annual value of $251.4 million for FY2024, which is 4655.12% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Other Non-Current Assets stood at $270.8 million for Q3 2025, which was up 3585.65% from $249.2 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Other Non-Current Assets registered a high of $270.8 million during Q3 2025, and its lowest value of $141.2 million during Q1 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's median Other Non-Current Assets value was $165.1 million (recorded in 2023), while the average stood at $180.1 million.
  • In the last 5 years, Biomarin Pharmaceutical's Other Non-Current Assets tumbled by 502.58% in 2023 and then surged by 4655.12% in 2024.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Other Non-Current Assets stood at $152.1 million in 2021, then increased by 15.85% to $176.2 million in 2022, then fell by 2.67% to $171.5 million in 2023, then skyrocketed by 46.55% to $251.4 million in 2024, then grew by 7.71% to $270.8 million in 2025.
  • Its last three reported values are $270.8 million in Q3 2025, $249.2 million for Q2 2025, and $235.7 million during Q1 2025.